UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September~~October 286, 2010

Dongsheng Pharmaceutical International Co., Ltd.

(Exact name of registrant as specified in its charter)

Delaware	333-154787	26-2603989
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

China Bing’qi Plaza, Floor 17, No 69,

Zi Zhu Yuan Rd, Hai’dian District, Beijing

People’s Republic of China 100089

(Address of principal executive offices)

+86-10-88580708

(Telephone number, including area code)

Copies to:

Joseph M. Lucosky, Esq.

Anslow & Jaclin LLP

195 Rt. 9 South, Suite 204

Manalapan, NJ, 07726

Tel.: (732) 409-1212

Fax: (732) 577-1188

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Director

Effective ~~September~~October 286, 2010, the board of directors of Dongsheng Pharmaceutical International Co., Ltd. (the “Company”) appointed MrRobert I. ~~Tsang-Bin~~Adler ~~Zeng~~ (the “Director”) to the Company’s board of directors (the “Board”). As of the date of this filing, Mr. ~~Zeng~~Adler has been appointed to the ~~Governance~~Audit ~~and Nominating~~ Committee of the Board.

~~Tsang-Bin~~Robert ~~Zeng~~I. Adler, age 5376, Director

Mr. ~~Zeng~~Adler currently serves as a director and chairman on the ~~Chief~~audit ~~Executive~~committee ~~Officer~~of the board of ~~SunTen~~directors ~~Phototech~~of Precision Aerospace Components, Inc. ~~(“SunTen”)~~, a ~~position~~stocking ~~which~~distributor heof ~~has~~precision ~~occupied~~fasteners ~~since~~based ~~2009.~~in ~~SunTen~~New isYork, ~~pharmaceutical~~NY ~~company~~(“POAC”). Mr. ~~focused~~Adler onhas ~~the~~served ~~development~~POAC ofin ~~novel~~this ~~botanical~~capacity ~~medicines~~since ~~and~~2006. From ~~functional~~April ~~dietary~~2006 ~~products.~~ to September 2010, Mr. ~~Zeng~~Adler isserved ~~responsible~~as ~~for~~a ~~all~~director and chairman of ~~aspects~~the ~~SunTen’s~~audit ~~operations~~committee of Sinoenergy Corporation, ~~development~~a developer and ~~fund~~operator ~~raising. From~~of ~~2002~~retail tocompressed ~~2009,~~natural ~~Mr.~~gas ~~Zeng~~(CNG) ~~was~~stations ~~the~~as ~~Senior~~well ~~Director~~as a manufacturer of ~~Experimental~~CNG ~~Medicine~~transport ~~and~~vehicles, ~~Clinical~~natural ~~Pharmacology~~gas atconversion ~~AstraZeneca~~kits ~~PLC~~for automobiles, aand ~~globally~~gas ~~integrated~~station ~~biopharmaceutical~~equipment ~~company~~in ~~(“AstraZeneca”)~~China. ~~While~~From atApril ~~AstraZeneca~~2006 until May 2010, Mr. ~~Zeng~~Adler ~~was~~served ~~responsible~~as ~~for~~a ~~providing~~director ~~clinical~~and ~~pharmacokinetic~~chairman ~~and~~of ~~pharmacodynamic~~the ~~expertise~~audit ~~for~~committee ~~multiple~~of ~~drug~~China ~~development~~Medicine ~~programs~~Corp., asa ~~well~~comprehensive asenterprise ~~managing~~engaging in the ~~activities~~production and distribution of ~~personnel~~prescription ~~associated~~and ~~with~~over the ~~conduct~~counter ofdrugs, ~~clinical~~traditional ~~studies~~Chinese medicine products, herbs and ~~assurance~~dietary-supplements, ofmedical ~~compliance~~devices, ~~with~~and ~~various~~medical ~~regulatory~~formulations ~~agencies~~in China. From ~~1998~~2002 to 2003, Mr. ~~Zeng~~Adler served as ~~the~~an ~~President~~investment ~~and~~advisor ~~Founder~~for ofUBS ~~MegaMed~~Financial ~~Pharmaceutical~~Services. In ~~Research Institute~~2002, aMr. ~~New~~Adler ~~Jersey~~served ~~based~~as ~~consulting~~managing ~~firm~~director for ~~major~~ING ~~pharmaceutical~~Furman ~~companies~~Selz Asset Management (“ING”). ~~Mr.~~Prior ~~Zeng~~to ~~received~~joining, aING, BMr.S. ~~degree~~Adler ~~from~~served ~~Taipei~~as ~~Medical~~the ~~University’s~~vice ~~School~~president ofand ~~Pharmacy~~senior ininvestment ~~1980. He~~officer ~~then~~of ~~received~~BHF aSecurities MCorp.S. ~~degree~~ from ~~National~~1991 ~~Taiwan~~to ~~University’s School of Pharmacy in 1982~~2000. Mr. ~~Zeng~~Adler ~~received~~obtained ~~his~~a PhB.DA. degree from ~~SUNY~~Swathmore ~~Buffalo~~College inand ~~1990. The~~is ~~Company~~a ~~believes~~member ~~that Mr. Zeng’s knowledge~~ of the ~~pharmaceutical~~Institute ~~industry~~of inChartered ~~both~~Financial ~~China~~Analysts and the ~~United~~New ~~States~~York ~~will~~Society ~~make him a vital member~~ of ~~the~~Security ~~Board~~Analysts.

The Company believes that Mr. Adler’s experience serving on the audit committees of other Chinese companies as well as his knowledge of the internal controls of public reporting companies makes him a key addition to the Board.

Family Relationships

Mr. ~~Zeng~~Adler does not have a family relationship with any of the officers or directors of the Company.

Related Party Transactions

There are no related party transactions reportable under Item 5.02 of Form 8-K and Item 404(a) of Regulation S-K.

Director Agreement

Pursuant to a director agreement, dated ~~September~~October 286, 2010 (the “Director Agreement”), Mr. ~~Zeng~~Adler was appointed to ~~board of directors of the Company~~Board. The Director Agreement is filed as Exhibit 10.1 to the current report on Form 8-K and is incorporated herein by reference.

The term of the Director Agreement is for a period of one year, commencing on ~~September~~October 286, 2010, and terminating on ~~September~~October 286, 2011, or the earliest of certain enumerated events in the Director Agreement (the “Term”). During the Term, the Company shall pay to the Director (i) $12,000 in quarterly installments, commencing on October 16, 2010 and (ii) $30,000 of stock options, such options to vest pursuant to the following schedule: (a) $10,000 of stock options to vest on October 16, 2011; (b) $10,000 of stock options to vest on October 16, 2012, contingent upon the renewal of the Director Agreement from ~~September~~October 296, 2011 to ~~September~~October 296, 2012; and (c) $10,000 of stock options to vest on October 16, 2013, contingent upon the renewal of the Director Agreement from ~~September~~October 296, 2012 to ~~September~~October 296, 2013.

The above description of the Director Agreement does not purport to be complete and is qualified in its entity by reference to such Director Agreement, which the Company has filed as Exhibit 10.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statement and Exhibits.

(d)

Exhibits

Exhibit Number	Description

10.1	Director Agreement by and between the Company and Mr. Robert Adler, effective October 6, 2010.

Exhibit Number	Description
10.1	Director Agreement by and between the Company and Mr. Tsang-Bin Zeng, effective September 28, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: October 1, 2010		DONGSHENG PHARMACEUTICAL INTERNATIONAL CO., LTD.
Dated: October 12, 2010		DONGSHENG PHARMACEUTICAL INTERNATIONAL CO., LTD.
	By:	/s/ Xiaodong Zhu
		Xiaodong Zhu Chief Executive Officer

Filing Compare · Dongsheng Pharmaceutical International Co., Ltd.